Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Irritable Bowel Syndrome

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 62 articles:
HTML format
Text format



Single Articles


    August 2017
  1. TACK J, Corsetti M, Camilleri M, Quigley EM, et al
    Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts.
    Gut. 2017 Aug 16. pii: gutjnl-2016-312230. doi: 10.1136/gutjnl-2016-312230.
    PubMed     Text format     Abstract available


    June 2017
  2. MAVRANGELOS C, Campaniello MA, Andrews JM, Bampton PA, et al
    Longitudinal analysis indicates symptom severity influences immune profile in irritable bowel syndrome.
    Gut. 2017 Jun 10. pii: gutjnl-2017-314308. doi: 10.1136/gutjnl-2017-314308.
    PubMed     Text format    


  3. DONNACHIE E, Schneider A, Mehring M, Enck P, et al
    Incidence of irritable bowel syndrome and chronic fatigue following GI infection: a population-level study using routinely collected claims data.
    Gut. 2017 Jun 10. pii: gutjnl-2017-313713. doi: 10.1136/gutjnl-2017-313713.
    PubMed     Text format     Abstract available


  4. STAUDACHER HM, Whelan K
    The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS.
    Gut. 2017 Jun 7. pii: gutjnl-2017-313750. doi: 10.1136/gutjnl-2017-313750.
    PubMed     Text format     Abstract available


    April 2017
  5. BENNET SMP, Bohn L, Storsrud S, Liljebo T, et al
    Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs.
    Gut. 2017 Apr 17. pii: gutjnl-2016-313128. doi: 10.1136/gutjnl-2016-313128.
    PubMed     Text format     Abstract available


    March 2017
  6. DE WINTER BY
    Identification of an epithelial member of the protease family, supporting the potential diagnostic and therapeutic role of serine proteases in IBS.
    Gut. 2017 Mar 10. pii: gutjnl-2016-313664. doi: 10.1136/gutjnl-2016-313664.
    PubMed     Text format    


  7. AN S, Zong G, Wang Z, Shi J, et al
    Activation of protease-activated receptor 4 of mast cells could downregulate proinflammatory cytokines in irritable bowel syndrome.
    Gut. 2017 Mar 8. pii: gutjnl-2016-313504. doi: 10.1136/gutjnl-2016-313504.
    PubMed     Text format    


    February 2017
  8. CAMILLERI M, Boeckxstaens G
    Dietary and pharmacological treatment of abdominal pain in IBS.
    Gut. 2017 Feb 23. pii: gutjnl-2016-313425. doi: 10.1136/gutjnl-2016-313425.
    PubMed     Text format     Abstract available


  9. WOUTERS MM
    Novel insight in diarrhoea-predominant IBS: miRNAs modulate barrier function.
    Gut. 2017 Feb 9. pii: gutjnl-2016-313525. doi: 10.1136/gutjnl-2016-313525.
    PubMed     Text format    


    January 2017
  10. SIMREN M, Tornblom H, Palsson OS, van Tilburg MA, et al
    Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts.
    Gut. 2017 Jan 19. pii: gutjnl-2016-312361. doi: 10.1136/gutjnl-2016-312361.
    PubMed     Text format     Abstract available


  11. ROLLAND-FOURCADE C, Denadai-Souza A, Cirillo C, Lopez C, et al
    Epithelial expression and function of trypsin-3 in irritable bowel syndrome.
    Gut. 2017 Jan 17. pii: gutjnl-2016-312094. doi: 10.1136/gutjnl-2016-312094.
    PubMed     Text format     Abstract available


  12. MARTINEZ C, Rodino-Janeiro BK, Lobo B, Stanifer ML, et al
    miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea.
    Gut. 2017 Jan 12. pii: gutjnl-2016-311477. doi: 10.1136/gutjnl-2016-311477.
    PubMed     Text format     Abstract available


    December 2016
  13. HENSTROM M, Hadizadeh F, Beyder A, Bonfiglio F, et al
    TRPM8 polymorphisms associated with increased risk of IBS-C and IBS-M.
    Gut. 2016 Dec 14. pii: gutjnl-2016-313346. doi: 10.1136/gutjnl-2016-313346.
    PubMed     Text format    


    November 2016
  14. HENSTROM M, Diekmann L, Bonfiglio F, Hadizadeh F, et al
    Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome.
    Gut. 2016 Nov 21. pii: gutjnl-2016-312456. doi: 10.1136/gutjnl-2016-312456.
    PubMed     Text format     Abstract available


    August 2016
  15. HOLVOET T, Joossens M, Wang J, Boelens J, et al
    Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating.
    Gut. 2016 Aug 10. pii: gutjnl-2016-312513. doi: 10.1136/gutjnl-2016-312513.
    PubMed     Text format    


    July 2016
  16. GOODSALL TM, Talley NJ, Rassam L, Wood NK, et al
    Unique pathology of colonic spirochaetosis characterised by mucosal eosinophilia is linked to diarrhoea and IBS.
    Gut. 2016 Jul 29. pii: gutjnl-2016-312405. doi: 10.1136/gutjnl-2016-312405.
    PubMed     Text format    


    April 2016
  17. TACK J, Schumacher K, Tonini G, Scartoni S, et al
    The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS.
    Gut. 2016 Apr 15. pii: gutjnl-2015-310683. doi: 10.1136/gutjnl-2015-310683.
    PubMed     Text format     Abstract available


    March 2016
  18. MCINTOSH K, Reed DE, Schneider T, Dang F, et al
    FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial.
    Gut. 2016 Mar 14. pii: gutjnl-2015-311339. doi: 10.1136/gutjnl-2015-311339.
    PubMed     Text format     Abstract available


    February 2016
  19. CASTRO J, Harrington AM, Garcia-Caraballo S, Maddern J, et al
    alpha-Conotoxin Vc1.1 inhibits human dorsal root ganglion neuroexcitability and mouse colonic nociception via GABAB receptors.
    Gut. 2016 Feb 17. pii: gutjnl-2015-310971. doi: 10.1136/gutjnl-2015-310971.
    PubMed     Text format     Abstract available


    January 2016
  20. SPERBER AD, Dumitrascu D, Fukudo S, Gerson C, et al
    The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review.
    Gut. 2016 Jan 27. pii: gutjnl-2015-311240. doi: 10.1136/gutjnl-2015-311240.
    PubMed     Text format     Abstract available


  21. WILDENBERG ME, van den Brink GR
    House dust mite: a new player in intestinal inflammation?
    Gut. 2016 Jan 13. pii: gutjnl-2015-311042. doi: 10.1136/gutjnl-2015-311042.
    PubMed     Text format    


    September 2015
  22. VALENTIN N, Camilleri M, Altayar O, Vijayvargiya P, et al
    Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis.
    Gut. 2015 Sep 7. pii: gutjnl-2015-309889. doi: 10.1136/gutjnl-2015-309889.
    PubMed     Text format     Abstract available


    July 2015
  23. WOUTERS MM, Vicario M, Santos J
    The role of mast cells in functional GI disorders.
    Gut. 2015 Jul 20. pii: gutjnl-2015-309151. doi: 10.1136/gutjnl-2015-309151.
    PubMed     Text format     Abstract available


    June 2015
  24. TORNBLOM H, Simren M
    In search for a disease-modifying treatment in irritable bowel syndrome.
    Gut. 2015 Jun 25. pii: gutjnl-2015-310024. doi: 10.1136/gutjnl-2015-310024.
    PubMed     Text format    


  25. DE GIORGIO R, Volta U, Gibson PR
    Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?
    Gut. 2015 Jun 15. pii: gutjnl-2015-309757. doi: 10.1136/gutjnl-2015-309757.
    PubMed     Text format     Abstract available


  26. WOUTERS M, Van Wanrooy S, Nguyen A, Dooley J, et al
    Psychological comorbidity increases the risk for postinfectious IBS partly by enhanced susceptibility to develop infectious gastroenteritis.
    Gut. 2015 Jun 12. pii: gutjnl-2015-309460. doi: 10.1136/gutjnl-2015-309460.
    PubMed     Text format     Abstract available


    April 2015
  27. MIN T, Ford AC
    Efficacy of mesalazine in IBS.
    Gut. 2015 Apr 14. pii: gutjnl-2015-309593. doi: 10.1136/gutjnl-2015-309593.
    PubMed     Text format    


    March 2015
  28. LAM C, Tan W, Leighton M, Hastings M, et al
    A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).
    Gut. 2015 Mar 12. pii: gutjnl-2015-309122. doi: 10.1136/gutjnl-2015-309122.
    PubMed     Text format     Abstract available


    February 2015
  29. ZHOU Q, Yang L, Larson S, Basra S, et al
    Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1.
    Gut. 2015 Feb 13. pii: gutjnl-2013-306464. doi: 10.1136/gutjnl-2013-306464.
    PubMed     Text format     Abstract available


    January 2015
  30. TAYLOR SJC, Pinnock H, Epiphaniou E, Pearce G, et al
    Diets that differ in their FODMAP content alter the colonic luminal microenvironment.
    Gut. 2015;64:93-100.
    PubMed     Text format     Abstract available


    December 2014
  31. BARBARA G, Cremon C, Annese V, Basilisco G, et al
    Randomised controlled trial of mesalazine in IBS.
    Gut. 2014 Dec 22. pii: gutjnl-2014-308188. doi: 10.1136/gutjnl-2014-308188.
    PubMed     Text format     Abstract available


    November 2014
  32. CAO DY, Bai G, Ji Y, Traub RJ, et al
    Epigenetic upregulation of metabotropic glutamate receptor 2 in the spinal cord attenuates oestrogen-induced visceral hypersensitivity.
    Gut. 2014 Nov 6. pii: gutjnl-2014-307748. doi: 10.1136/gutjnl-2014-307748.
    PubMed     Text format     Abstract available


    September 2014
  33. EK WE, Reznichenko A, Ripke S, Niesler B, et al
    Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts.
    Gut. 2014 Sep 23. pii: gutjnl-2014-307997. doi: 10.1136/gutjnl-2014-307997.
    PubMed     Text format     Abstract available


  34. VICARIO M, Gonzalez-Castro AM, Martinez C, Lobo B, et al
    Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations.
    Gut. 2014 Sep 10. pii: gutjnl-2013-306236. doi: 10.1136/gutjnl-2013-306236.
    PubMed     Text format     Abstract available


    July 2014
  35. BAJOR A, Tornblom H, Rudling M, Ung KA, et al
    Authors' response: Bile acids are important in the pathophysiology of IBS.
    Gut. 2014 Jul 23. pii: gutjnl-2014-308037. doi: 10.1136/gutjnl-2014-308037.
    PubMed     Text format    


    June 2014
  36. ACRES M, Owen S, Rigby R
    LB-005 Post-infection Dysbiosis - A Potential Cause Of Irritable Bowel Syndrome?
    Gut. 2014;63 Suppl 1:e2.
    PubMed     Text format     Abstract available


  37. BUNDHOO K, Aravinthan A, Lithgo K, Price T, et al
    PTU-096 Cost Efficiency Of Faecal Calprotectin In Assessing New Referrals With Altered Bowel Habit.
    Gut. 2014;63 Suppl 1:A81.
    PubMed     Text format     Abstract available


  38. AZIZ I, Winfield S, Kelsall A, Rugg N, et al
    PTU-088 Non-coeliac Gluten Sensitivity Can Be Present In Inflammatory Bowel Disease, Not Just Irritable Bowel Syndrome.
    Gut. 2014;63 Suppl 1:A78.
    PubMed     Text format     Abstract available


  39. LAM C, Tan W, Leighton M, Williams J, et al
    OC-069 Mesalazine For Treatment Of Diarrhoea-predominant Irritable Bowel Syndrome (ibs-d): A Multi-centre, Parallel Group, Randomised Placebo Controlled Trial.
    Gut. 2014;63 Suppl 1:A34.
    PubMed     Text format     Abstract available


  40. KURIEN M, Gleeson J, Osborne C, Messham L, et al
    PTH-110 Factors Predictive Of Bile Acid Diarrhoea And Long Term Treatment Outcomes.
    Gut. 2014;63 Suppl 1:A259-60.
    PubMed     Text format     Abstract available


  41. AZIZ I, Mumtaz S, Bholah H, Chowdhury F, et al
    PTH-106 Bile Acid Diarrhoea Masquerades As Diarrhoea-predominant Irritable Bowel Syndrome: Results From A Dual Centre Prospective Study.
    Gut. 2014;63 Suppl 1:A257-8.
    PubMed     Text format     Abstract available


  42. KINRADE S, Twamley R, Fell L, Heald L, et al
    PTH-066 An Audit To Assess Feasibility And Efficacy Of Group Education For Irritable Bowel Syndrome (ibs) Patients In The Delivery Of Low Fodmap (fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols) Dietary Advice.
    Gut. 2014;63 Suppl 1:A238.
    PubMed     Text format     Abstract available


  43. SHIVAJI U, Ford A
    PWE-185 Beliefs About Management Of Irritable Bowel Syndrome In Primary Care: Cross-sectional Survey.
    Gut. 2014;63 Suppl 1:A207.
    PubMed     Text format     Abstract available


  44. ANDRESEN V, Whorwell P, Fortea J, Milce J, et al
    PWE-180 A Survey Evaluating General Practitioners', Gastroenterologists' And Experts' Diagnostic Approaches To Inflammatory Bowel Disease, Irritable Bowel Syndrome And Chronic Constipation In Five European Countries.
    Gut. 2014;63 Suppl 1:A204-5.
    PubMed     Text format     Abstract available


  45. RADFORD M, Bloomfield E, Joseph A
    PWE-178 Impact Of Chronic Constipation On Healthcare Resource Use In The Uk: An Analysis Based On Electronic Medical Records.
    Gut. 2014;63 Suppl 1:A203-4.
    PubMed     Text format     Abstract available


  46. RANCE M, Lindner L, Ford A
    PWE-177 A Systematic Review Of Antidepressants In Irritable Bowel Syndrome: A Qualitative Analysis.
    Gut. 2014;63 Suppl 1:A203.
    PubMed     Text format     Abstract available


  47. MCTAGGART S, Wyper G, Harkins L, Bishop I, et al
    PWE-176 Prevalence, Management, And Healthcare Burden Of Irritable Bowel Syndrome (ibs) In Scotland.
    Gut. 2014;63 Suppl 1:A202-3.
    PubMed     Text format     Abstract available


  48. FISHER M, Walker A, Falques M, Rance M, et al
    PWE-175 Cost-effectiveness Of Linaclotide (lin) Compared To Antidepressants (atds) In The Treatment Of Irritable Bowel Syndrome With Constipation (ibs-c) In Scotland.
    Gut. 2014;63 Suppl 1:A202.
    PubMed     Text format     Abstract available


  49. MCGEOCH V, Blackwell V, Wigham L, Hoare J, et al
    PWE-170 An Audit Of Clinical Response In Patients With Ibs Treated With The Low Fodmap Diet At St Mary's Hospital.
    Gut. 2014;63 Suppl 1:A199-200.
    PubMed     Text format     Abstract available


  50. HAYMAN J, Pickering G, Sanders D
    PWE-168 Is There A Relationship Between Irritable Bowel Syndrome Symptoms And Small Bowel Bacterial Overgrowth?
    Gut. 2014;63.
    PubMed     Text format     Abstract available


  51. CURRIE M, Shiff S, Hao X, Carson R, et al
    PWE-167 Effect Of Linaclotide On Ibs-qol Sexual Subscale Scores In Patients With Irritable Bowel Syndrome With Constipation: Results From 2 Phase 3 Trials.
    Gut. 2014;63 Suppl 1:A198.
    PubMed     Text format     Abstract available


  52. CHEY W, Lavins B, Shiff S, MacDougall J, et al
    PWE-166 Is Response To Linaclotide After 4 Weeks Of Treatment Predictive Of 12-week Improvement?
    Gut. 2014;63 Suppl 1:A197-8.
    PubMed     Text format     Abstract available


  53. CALDWELL I, Collins J, Rance M, Dew R, et al
    PWE-165 A Real World Study To Describe The Patient Pathways And Nhs Resource Use Associated With The Management Of Irritable Bowel Syndrome (ibs) In Uk Clinical Practice.
    Gut. 2014;63 Suppl 1:A197.
    PubMed     Text format     Abstract available


  54. COOKE J, Clamp P, Haigney D, Rostami K, et al
    PWE-162 An Audit Of Testing For Coeliac Disease In Patients Diagnosed With The Irritable Bowel Syndrome At A Large Primary Care Centre.
    Gut. 2014;63 Suppl 1:A195-6.
    PubMed     Text format     Abstract available


  55. LAM C, Chaddock G, Hoad C, Costigan C, et al
    PWE-161 The Macrogol Drink Test To Distinguish Functional Constipation (fc) And Constipation Predominant Irritable Bowel Syndrome (ibs-c): Underlying Mechanisms Demonstrated Using Mri.
    Gut. 2014;63 Suppl 1:A195.
    PubMed     Text format     Abstract available


  56. WILSON P, Poullis A, Wilkins J, Rance M, et al
    PWE-159 The Costs Of Irritable Bowel Syndrome (ibs) In An Increasingly Cost Aware Nhs.
    Gut. 2014;63 Suppl 1:A194.
    PubMed     Text format     Abstract available


  57. DHARMASIRI S, Boud R, Dower A, Hennessy N, et al
    PWE-113 Diagnostic Benefit Of Mre Following Ct.
    Gut. 2014;63 Suppl 1:A174.
    PubMed     Text format     Abstract available


  58. HUNT N, Allcock R, Sharma A, Myers M, et al
    PWE-081 Diagnostic Performance Of Faecal Calprotectin In Primary Care.
    Gut. 2014;63 Suppl 1:A159.
    PubMed     Text format     Abstract available


  59. CHHAYA V, Poullis A, Bandaletova T, Loktionov A, et al
    PWE-022 Patient Acceptability Of A Novel, Non-invasive Method Of Colonic Sampling For Biomarker Analysis.
    Gut. 2014;63 Suppl 1:A131.
    PubMed     Text format     Abstract available


  60. COVINGTON J, McFarlane M, Harbord R, Westenbrink E, et al
    PTU-163 Urinary Volatile Organic Compound Analysis To Distinguish Coeliac Disease From Irritable Bowel Syndrome: A Pilot Study.
    Gut. 2014;63 Suppl 1:A110.
    PubMed     Text format     Abstract available


    May 2014
  61. AZIZ I, Kurien M, Sanders DS, Ford AC, et al
    Screening for bile acid diarrhoea in suspected irritable bowel syndrome.
    Gut. 2014 May 28. pii: gutjnl-2014-307579. doi: 10.1136/gutjnl-2014-307579.
    PubMed     Text format    


  62. LUTHRA P, Ford AC
    Ondansetron and irritable bowel syndrome.
    Gut. 2014 May 20. pii: gutjnl-2014-307551. doi: 10.1136/gutjnl-2014-307551.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Irritable Bowel Syndrome is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: